Clinical Trials Logo

Clinical Trial Summary

Given that GADD34 has been described as a potential key regulator of pro-inflammatory cytokine production in human and elevated blood marker in SLE patients, this study aim to prove that the GADD34 RNA level in mononuclear blood cells can be used as a prognostic marker to assess the risk of SLE flare.


Clinical Trial Description

Systemic lupus erythematosus (SLE) has a prevalence estimated between 1 and 6 per 10000 individuals and concerns over 30 000 patients in France for example. As of today, there isn't any reliable specific blood analysis that can be used to assess the prognosis of SLE, that means predict a SLE flare. The discovery of such a blood test could allow a better patients' monitoring in order to help doctors to better adapt treatments (lowering background treatments when they are not needed and increase them ahead of a potential flare when the risk assessment raises).

In SLE patients, a recent study shows elevated levels of GADD34 RNA in mononuclear blood cells : higher than twice the control levels for 36 of the 60 SLE patients and ten times higher than the control levels for 13 of the 60 SLE patients.

Given that GADD34 has been described as a potential key regulator of pro-inflammatory cytokine production in human and elevated blood marker in SLE patients, this study aim to prove that the GADD34 RNA level in mononuclear blood cells can be used as a prognostic marker to assess the risk of SLE flare. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02455089
Study type Interventional
Source University Hospital, Grenoble
Contact
Status Completed
Phase N/A
Start date June 2015
Completion date February 2019

See also
  Status Clinical Trial Phase
Recruiting NCT03543839 - Trial of Belimumab in Early Lupus Phase 4
Terminated NCT02080195 - Nonmyeloablative Conditioning and Transplantation for Patients With Refractory Systemic Lupus Erythematosus (SLE) Phase 1/Phase 2
Completed NCT03098823 - A Crossover Study to Compare RAYOS to IR Prednisone to Improve Fatigue and Morning Symptoms for SLE Phase 4
Recruiting NCT03562065 - Treatment of Refractory Systemic Lupus Erythematosus by Allogeneic Mesenchymal Stem Cells Derived From the Umbilical Cord Phase 1/Phase 2
Recruiting NCT05545839 - Transition to Adulthood Through Coaching and Empowerment in Rheumatology N/A
Completed NCT05098600 - The Epidemiology, Management and Comorbidities in Alopecia Areata in Czech Republic
Completed NCT04128579 - Study of EQ001 (Itolizumab) in Systemic Lupus Erythematosus With or Without Active Proliferative Nephritis Phase 1
Recruiting NCT06161363 - Description of Compliance With Hydroxychloroquine Treatment in Patients With Systemic Lupus Erythematosus
Completed NCT03421184 - Dietary Phytoestrogens as Risk Factors for Systemic Lupus Erythematosus N/A
Not yet recruiting NCT02891213 - Study of the Role of Soluble Forms of RAGE (sRAGE/esRAGE) as Diagnostic and Prognostic Biomarkers of Systemic Lupus Erythematosus. N/A
Completed NCT01686555 - A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ABT-199 in Female Patients With Systemic Lupus Erythematosus (SLE) Phase 1
Active, not recruiting NCT04018222 - Translation of a Diagnostic Test for Lupus Flare Prediction From Bench to Clinic
Completed NCT02747277 - Analysis of B Cells From Autoimmune Individuals
Not yet recruiting NCT06426316 - The Role of Cytokines and Regulatory T Lymphocytes in Migraine Pathophysiology. N/A
Recruiting NCT04213690 - A Pilot Study to Explore the Role of Gut Flora in Lupus
Recruiting NCT03913754 - Psycho-social Consequences of Systemic Lupus Erythematosus
Recruiting NCT06072287 - The Living With a Long-Term Condition Study
Completed NCT04089930 - Long-term Immunogenicity of a Live Herpes Zoster Vaccine in Systemic Lupus Erythematosus (SLE) Patients
Completed NCT05945784 - Exploring Accessible Beauty for Individuals With Upper Extremity Deficits
Completed NCT03253666 - Nurses' Health Study and Health Professionals Follow-Up Study (Dermatological Component)